ID   EPHA2_HUMAN             Reviewed;         976 AA.
AC   P29317; B5A968; Q8N3Z2;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 2.
DT   10-MAY-2017, entry version 203.
DE   RecName: Full=Ephrin type-A receptor 2;
DE            EC=2.7.10.1;
DE   AltName: Full=Epithelial cell kinase;
DE   AltName: Full=Tyrosine-protein kinase receptor ECK;
DE   Flags: Precursor;
GN   Name=EPHA2; Synonyms=ECK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY, AND
RP   AUTOPHOSPHORYLATION.
RC   TISSUE=Epithelium;
RX   PubMed=2174105; DOI=10.1128/MCB.10.12.6316;
RA   Lindberg R.A., Hunter T.;
RT   "cDNA cloning and characterization of eck, an epithelial cell receptor
RT   protein-tyrosine kinase in the eph/elk family of protein kinases.";
RL   Mol. Cell. Biol. 10:6316-6324(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING.
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NOMENCLATURE.
RX   PubMed=9267020;
RG   Eph nomenclature committee;
RT   "Unified nomenclature for Eph family receptors and their ligands, the
RT   ephrins.";
RL   Cell 90:403-404(1997).
RN   [7]
RP   FUNCTION IN INTEGRIN-MEDIATED CELL ADHESION, FUNCTION IN CELL
RP   MIGRATION, PHOSPHORYLATION, INTERACTION WITH PTK2/FAK1 AND PTPN11, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=10655584; DOI=10.1038/35000008;
RA   Miao H., Burnett E., Kinch M., Simon E., Wang B.;
RT   "Activation of EphA2 kinase suppresses integrin function and causes
RT   focal-adhesion-kinase dephosphorylation.";
RL   Nat. Cell Biol. 2:62-69(2000).
RN   [8]
RP   ONCOGENICITY.
RX   PubMed=11280802;
RA   Zelinski D.P., Zantek N.D., Stewart J.C., Irizarry A.R., Kinch M.S.;
RT   "EphA2 overexpression causes tumorigenesis of mammary epithelial
RT   cells.";
RL   Cancer Res. 61:2301-2306(2001).
RN   [9]
RP   INTERACTION WITH ACP1, AND DEPHOSPHORYLATION BY ACP1.
RX   PubMed=12167657; DOI=10.1074/jbc.M207127200;
RA   Kikawa K.D., Vidale D.R., Van Etten R.L., Kinch M.S.;
RT   "Regulation of the EphA2 kinase by the low molecular weight tyrosine
RT   phosphatase induces transformation.";
RL   J. Biol. Chem. 277:39274-39279(2002).
RN   [10]
RP   FUNCTION IN CELL-CELL INTERACTION, INTERACTION WITH CLDN4, AND
RP   MUTAGENESIS OF LYS-646.
RX   PubMed=16236711; DOI=10.1074/jbc.M503786200;
RA   Tanaka M., Kamata R., Sakai R.;
RT   "EphA2 phosphorylates the cytoplasmic tail of Claudin-4 and mediates
RT   paracellular permeability.";
RL   J. Biol. Chem. 280:42375-42382(2005).
RN   [11]
RP   TISSUE SPECIFICITY.
RX   PubMed=17332925;
RA   Liu D.-P., Wang Y., Koeffler H.P., Xie D.;
RT   "Ephrin-A1 is a negative regulator in glioma through down-regulation
RT   of EphA2 and FAK.";
RL   Int. J. Oncol. 30:865-871(2007).
RN   [12]
RP   INTERACTION WITH INPPL1.
RX   PubMed=17135240; DOI=10.1074/jbc.M608509200;
RA   Zhuang G., Hunter S., Hwang Y., Chen J.;
RT   "Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase
RT   via phosphatidylinositol 3-Kinase-dependent Rac1 activation.";
RL   J. Biol. Chem. 282:2683-2694(2007).
RN   [13]
RP   FUNCTION IN APOPTOSIS, AND INDUCTION BY UV.
RX   PubMed=18339848; DOI=10.1158/0008-5472.CAN-07-2372;
RA   Zhang G., Njauw C.-N., Park J.M., Naruse C., Asano M., Tsao H.;
RT   "EphA2 is an essential mediator of UV radiation-induced apoptosis.";
RL   Cancer Res. 68:1691-1696(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; SER-579 AND
RP   THR-647, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [15]
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=18794797; DOI=10.1038/onc.2008.328;
RA   Wykosky J., Palma E., Gibo D.M., Ringler S., Turner C.P., Debinski W.;
RT   "Soluble monomeric EphrinA1 is released from tumor cells and is a
RT   functional ligand for the EphA2 receptor.";
RL   Oncogene 27:7260-7273(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; SER-892 AND
RP   SER-901, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   DISEASE, FUNCTION IN CELL MIGRATION, SUBCELLULAR LOCATION, MUTAGENESIS
RP   OF ASP-739 AND SER-897, AND PHOSPHORYLATION AT SER-897 BY PKB.
RX   PubMed=19573808; DOI=10.1016/j.ccr.2009.04.009;
RA   Miao H., Li D.Q., Mukherjee A., Guo H., Petty A., Cutter J.,
RA   Basilion J.P., Sedor J., Wu J., Danielpour D., Sloan A.E., Cohen M.L.,
RA   Wang B.;
RT   "EphA2 mediates ligand-dependent inhibition and ligand-independent
RT   promotion of cell migration and invasion via a reciprocal regulatory
RT   loop with Akt.";
RL   Cancer Cell 16:9-20(2009).
RN   [18]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-435.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [19]
RP   UBIQUITINATION BY STUB1.
RX   PubMed=19567782; DOI=10.1158/1541-7786.MCR-08-0582;
RA   Annamalai B., Liu X., Gopal U., Isaacs J.S.;
RT   "Hsp90 is an essential regulator of EphA2 receptor stability and
RT   signaling: implications for cancer cell migration and metastasis.";
RL   Mol. Cancer Res. 7:1021-1032(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; TYR-628; THR-647
RP   AND SER-869, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [21]
RP   FUNCTION IN CELL MIGRATION, AND INTERACTION WITH ARHGEF16; DOCK4 AND
RP   ELMO2.
RX   PubMed=20679435; DOI=10.1083/jcb.201005141;
RA   Hiramoto-Yamaki N., Takeuchi S., Ueda S., Harada K., Fujimoto S.,
RA   Negishi M., Katoh H.;
RT   "Ephexin4 and EphA2 mediate cell migration through a RhoG-dependent
RT   mechanism.";
RL   J. Cell Biol. 190:461-477(2010).
RN   [22]
RP   FUNCTION IN KERATINOCYTE ADHESION AND DIFFERENTIATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=20861311; DOI=10.1091/mbc.E10-03-0242;
RA   Lin S., Gordon K., Kaplan N., Getsios S.;
RT   "Ligand targeting of EphA2 enhances keratinocyte adhesion and
RT   differentiation via desmoglein 1.";
RL   Mol. Biol. Cell 21:3902-3914(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   INTERACTION WITH ANKS1A.
RX   PubMed=22332920; DOI=10.1021/bi300141h;
RA   Mercurio F.A., Marasco D., Pirone L., Pedone E.M., Pellecchia M.,
RA   Leone M.;
RT   "Solution structure of the first Sam domain of Odin and binding
RT   studies with the EphA2 receptor.";
RL   Biochemistry 51:2136-2145(2012).
RN   [26]
RP   INTERACTION WITH HHV-8 GLYCOPROTEIN L/GLYCOPROTEIN H (MICROBIAL
RP   INFECTION).
RX   PubMed=22635007; DOI=10.1038/nm.2805;
RA   Hahn A.S., Kaufmann J.K., Wies E., Naschberger E., Panteleev-Ivlev J.,
RA   Schmidt K., Holzer A., Schmidt M., Chen J., Konig S., Ensser A.,
RA   Myoung J., Brockmeyer N.H., Sturzl M., Fleckenstein B., Neipel F.;
RT   "The ephrin receptor tyrosine kinase A2 is a cellular receptor for
RT   Kaposi's sarcoma-associated herpesvirus.";
RL   Nat. Med. 18:961-966(2012).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-575; SER-892; SER-897
RP   AND SER-901, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [28]
RP   FUNCTION IN CELL MIGRATION, PHOSPHORYLATION AT TYR-930,
RP   DEPHOSPHORYLATION AT TYR-930 BY PTPRF, AND INTERACTION WITH NCK1.
RX   PubMed=23358419; DOI=10.1128/MCB.01708-12;
RA   Lee H., Bennett A.M.;
RT   "Receptor protein tyrosine phosphatase-receptor tyrosine kinase
RT   substrate screen identifies EphA2 as a target for LAR in cell
RT   migration.";
RL   Mol. Cell. Biol. 33:1430-1441(2013).
RN   [29]
RP   INTERACTION WITH CEMIP.
RX   PubMed=23936024; DOI=10.1371/journal.pone.0069473;
RA   Tiwari A., Schneider M., Fiorino A., Haider R., Okoniewski M.J.,
RA   Roschitzki B., Uzozie A., Menigatti M., Jiricny J., Marra G.;
RT   "Early insights into the function of KIAA1199, a markedly
RT   overexpressed protein in human colorectal tumors.";
RL   PLoS ONE 8:E69473-E69473(2013).
RN   [30]
RP   PHOSPHORYLATION AT SER-897 BY RPS6KA1 AND RPS6KA3, AND FUNCTION IN
RP   CELL MIGRATION.
RX   PubMed=26158630; DOI=10.1038/ncomms8679;
RA   Zhou Y., Yamada N., Tanaka T., Hori T., Yokoyama S., Hayakawa Y.,
RA   Yano S., Fukuoka J., Koizumi K., Saiki I., Sakurai H.;
RT   "Crucial roles of RSK in cell motility by catalysing serine
RT   phosphorylation of EphA2.";
RL   Nat. Commun. 6:7679-7679(2015).
RN   [31]
RP   PHOSPHORYLATION AT SER-897 BY PKA, PHOSPHORYLATION AT SER-901, AND
RP   FUNCTION.
RX   PubMed=27385333; DOI=10.1091/mbc.E16-01-0048;
RA   Barquilla A., Lamberto I., Noberini R., Heynen-Genel S., Brill L.M.,
RA   Pasquale E.B.;
RT   "Protein kinase A can block EphA2 receptor-mediated cell repulsion by
RT   increasing EphA2 S897 phosphorylation.";
RL   Mol. Biol. Cell 27:2757-2770(2016).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 596-900.
RX   PubMed=12467573; DOI=10.1016/S0969-2126(02)00907-3;
RA   Nowakowski J., Cronin C.N., McRee D.E., Knuth M.W., Nelson C.G.,
RA   Pavletich N.P., Rogers J., Sang B.C., Scheibe D.N., Swanson R.V.,
RA   Thompson D.A.;
RT   "Structures of the cancer-related Aurora-A, FAK, and EphA2 protein
RT   kinases from nanovolume crystallography.";
RL   Structure 10:1659-1667(2002).
RN   [33]
RP   STRUCTURE BY NMR OF 902-976.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the C-terminal SAM-domain of EPHAA2: ephrin
RT   type-A receptor 2 precursor (EC 2.7.10.1).";
RL   Submitted (JAN-2008) to the PDB data bank.
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 28-201, X-RAY
RP   CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 28-201 IN COMPLEX WITH EFNA1,
RP   SUBUNIT, DISULFIDE BOND, AND MUTAGENESIS OF ARG-103.
RX   PubMed=19525919; DOI=10.1038/embor.2009.91;
RA   Himanen J.P., Goldgur Y., Miao H., Myshkin E., Guo H., Buck M.,
RA   Nguyen M., Rajashankar K.R., Wang B., Nikolov D.B.;
RT   "Ligand recognition by A-class Eph receptors: crystal structures of
RT   the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex.";
RL   EMBO Rep. 10:722-728(2009).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 25-202, AND DISULFIDE BOND.
RG   Structural genomics consortium (SGC);
RT   "Ephrin A1 bound to the ligand binding domain of the human ephrin A2
RT   (EPHA2) receptor protein kinase.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [36]
RP   STRUCTURE BY NMR OF 523-563.
RA   Mayzel M.L., Bocharov E.V., Volynsky P.E., Arseniev A.S.;
RT   "Left-handed dimer of EPHA2 transmembrane domain helix packing
RT   diversity among receptor tyrosine kinases.";
RL   Submitted (AUG-2009) to the PDB data bank.
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 23-202 IN COMPLEX WITH
RP   EFNA1, AND SUBUNIT.
RX   PubMed=20505120; DOI=10.1073/pnas.1004148107;
RA   Himanen J.P., Yermekbayeva L., Janes P.W., Walker J.R., Xu K.,
RA   Atapattu L., Rajashankar K.R., Mensinga A., Lackmann M., Nikolov D.B.,
RA   Dhe-Paganon S.;
RT   "Architecture of Eph receptor clusters.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:10860-10865(2010).
RN   [38]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-391; MET-511; HIS-568; SER-777 AND
RP   HIS-876.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [39]
RP   VARIANT CTRCT6 TRP-948.
RX   PubMed=19005574;
RA   Shiels A., Bennett T.M., Knopf H.L.S., Maraini G., Li A., Jiao X.,
RA   Hejtmancik J.F.;
RT   "The EPHA2 gene is associated with cataracts linked to chromosome
RT   1p.";
RL   Mol. Vis. 14:2042-2055(2008).
RN   [40]
RP   VARIANT CTRCT6 ILE-940.
RX   PubMed=19306328; DOI=10.1002/humu.20995;
RA   Zhang T., Hua R., Xiao W., Burdon K.P., Bhattacharya S.S., Craig J.E.,
RA   Shang D., Zhao X., Mackey D.A., Moore A.T., Luo Y., Zhang J.,
RA   Zhang X.;
RT   "Mutations of the EPHA2 receptor tyrosine kinase gene cause autosomal
RT   dominant congenital cataract.";
RL   Hum. Mutat. 30:E603-E611(2009).
RN   [41]
RP   VARIANT CTRCT6 GLN-721, AND CHARACTERIZATION OF VARIANT CTRCT6
RP   GLN-721.
RX   PubMed=19649315; DOI=10.1371/journal.pgen.1000584;
RA   Jun G., Guo H., Klein B.E., Klein R., Wang J.J., Mitchell P., Miao H.,
RA   Lee K.E., Joshi T., Buck M., Chugha P., Bardenstein D., Klein A.P.,
RA   Bailey-Wilson J.E., Gong X., Spector T.D., Andrew T., Hammond C.J.,
RA   Elston R.C., Iyengar S.K., Wang B.;
RT   "EPHA2 is associated with age-related cortical cataract in mice and
RT   humans.";
RL   PLoS Genet. 5:E1000584-E1000584(2009).
RN   [42]
RP   CHARACTERIZATION OF VARIANTS CTRCT6 ILE-940 AND CTRCT6 TRP-948.
RX   PubMed=22570727; DOI=10.1371/journal.pone.0036564;
RA   Park J.E., Son A.I., Hua R., Wang L., Zhang X., Zhou R.;
RT   "Human cataract mutations in EPHA2 SAM domain alter receptor stability
RT   and function.";
RL   PLoS ONE 7:E36564-E36564(2012).
CC   -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously
CC       membrane-bound ephrin-A family ligands residing on adjacent cells,
CC       leading to contact-dependent bidirectional signaling into
CC       neighboring cells. The signaling pathway downstream of the
CC       receptor is referred to as forward signaling while the signaling
CC       pathway downstream of the ephrin ligand is referred to as reverse
CC       signaling. Activated by the ligand ephrin-A1/EFNA1 regulates
CC       migration, integrin-mediated adhesion, proliferation and
CC       differentiation of cells. Regulates cell adhesion and
CC       differentiation through DSG1/desmoglein-1 and inhibition of the
CC       ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. May also
CC       participate in UV radiation-induced apoptosis and have a ligand-
CC       independent stimulatory effect on chemotactic cell migration.
CC       During development, may function in distinctive aspects of pattern
CC       formation and subsequently in development of several fetal
CC       tissues. Involved for instance in angiogenesis, in early hindbrain
CC       development and epithelial proliferation and branching
CC       morphogenesis during mammary gland development. Engaged by the
CC       ligand ephrin-A5/EFNA5 may regulate lens fiber cells shape and
CC       interactions and be important for lens transparency development
CC       and maintenance. With ephrin-A2/EFNA2 may play a role in bone
CC       remodeling through regulation of osteoclastogenesis and
CC       osteoblastogenesis. {ECO:0000269|PubMed:10655584,
CC       ECO:0000269|PubMed:16236711, ECO:0000269|PubMed:18339848,
CC       ECO:0000269|PubMed:19573808, ECO:0000269|PubMed:20679435,
CC       ECO:0000269|PubMed:20861311, ECO:0000269|PubMed:23358419,
CC       ECO:0000269|PubMed:26158630, ECO:0000269|PubMed:27385333}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:2174105}.
CC   -!- SUBUNIT: Homodimer. Interacts with SLA. Interacts (phosphorylated
CC       form) with VAV2, VAV3 and PI3-kinase p85 subunit (PIK3R1, PIK3R2
CC       or PIK3R3); critical for the EFNA1-induced activation of RAC1
CC       which stimulates cell migration (By similarity). Interacts with
CC       INPPL1; regulates activated EPHA2 endocytosis and degradation.
CC       Interacts (inactivated form) with PTK2/FAK1 and interacts (EFNA1
CC       ligand-activated form) with PTPN11; regulates integrin-mediated
CC       adhesion. Interacts with ARHGEF16, DOCK4 and ELMO2; mediates
CC       ligand-independent activation of RAC1 which stimulates cell
CC       migration. Interacts with CLDN4; phosphorylates CLDN4 and may
CC       regulate tight junctions. Interacts with ACP1. Interacts (via SAM
CC       domain) with ANKS1A (via SAM domain). Interacts with CEMIP.
CC       Interacts with NCK1; may regulate EPHA2 activity in cell migration
CC       and adhesion. {ECO:0000250|UniProtKB:Q03145,
CC       ECO:0000269|PubMed:10655584, ECO:0000269|PubMed:12167657,
CC       ECO:0000269|PubMed:16236711, ECO:0000269|PubMed:17135240,
CC       ECO:0000269|PubMed:19525919, ECO:0000269|PubMed:20505120,
CC       ECO:0000269|PubMed:20679435, ECO:0000269|PubMed:22332920,
CC       ECO:0000269|PubMed:23358419, ECO:0000269|PubMed:23936024}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human herpes virus
CC       8/HHV-8 glycoprotein L/gL and glycoprotein H/gH heterodimer; this
CC       interaction triggers EPHA2 phosphorylation and endocytosis,
CC       allowing virus entry. {ECO:0000269|PubMed:22635007}.
CC   -!- INTERACTION:
CC       P20827:EFNA1; NbExp=7; IntAct=EBI-702104, EBI-715194;
CC       Q15375:EPHA7; NbExp=3; IntAct=EBI-702104, EBI-1383428;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-702104, EBI-352572;
CC       Q05397:PTK2; NbExp=3; IntAct=EBI-702104, EBI-702142;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18794797,
CC       ECO:0000269|PubMed:19573808, ECO:0000269|PubMed:20861311}; Single-
CC       pass type I membrane protein {ECO:0000255}. Cell projection,
CC       ruffle membrane {ECO:0000269|PubMed:19573808}; Single-pass type I
CC       membrane protein {ECO:0000255}. Cell projection, lamellipodium
CC       membrane {ECO:0000269|PubMed:19573808}; Single-pass type I
CC       membrane protein {ECO:0000255}. Cell junction, focal adhesion
CC       {ECO:0000269|PubMed:10655584}. Note=Present at regions of cell-
CC       cell contacts but also at the leading edge of migrating cells
CC       (PubMed:19573808, PubMed:20861311). Relocates from the plasma
CC       membrane to the cytoplasmic and perinuclear regions in cancer
CC       cells (PubMed:18794797). {ECO:0000269|PubMed:18794797,
CC       ECO:0000269|PubMed:19573808, ECO:0000269|PubMed:20861311,
CC       ECO:0000269|PubMed:26158630}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P29317-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P29317-2; Sequence=VSP_056014, VSP_056015;
CC   -!- TISSUE SPECIFICITY: Expressed in brain and glioma tissue and
CC       glioma cell lines (at protein level). Expressed most highly in
CC       tissues that contain a high proportion of epithelial cells, e.g.
CC       skin, intestine, lung, and ovary. {ECO:0000269|PubMed:17332925}.
CC   -!- INDUCTION: Up-regulated by UV irradiation via a TP53-independent,
CC       MAPK-dependent mechanism. {ECO:0000269|PubMed:18339848}.
CC   -!- PTM: Autophosphorylates. Phosphorylated on tyrosine upon binding
CC       and activation by EFNA1. Phosphorylated residues Tyr-588 and Tyr-
CC       594 are required for binding VAV2 and VAV3 while phosphorylated
CC       residues Tyr-735 and Tyr-930 are required for binding PI3-kinase
CC       p85 subunit (PIK3R1, PIK3R2 or PIK3R3). These phosphorylated
CC       residues are critical for recruitment of VAV2 and VAV3 and PI3-
CC       kinase p85 subunit which transduce downstream signaling to
CC       activate RAC1 GTPase and cell migration. Dephosphorylation of Tyr-
CC       930 by PTPRF prevents the interaction of EPHA2 with NCK1.
CC       Phosphorylated at Ser-897 by PKB; serum-induced phosphorylation
CC       which targets EPHA2 to the cell leading edge and stimulates cell
CC       migration. Phosphorylation by PKB is inhibited by EFNA1-activated
CC       EPHA2 which regulates PKB activity via a reciprocal regulatory
CC       loop. Phosphorylated at Ser-897 in response to TNF by RPS6KA1 and
CC       RPS6KA3; RPS6KA-EPHA2 signaling pathway controls cell migration
CC       (PubMed:26158630). Phosphorylated at Ser-897 by PKA; blocks cell
CC       retraction induced by EPHA2 kinase activity (PubMed:27385333).
CC       Dephosphorylated by ACP1. {ECO:0000269|PubMed:10655584,
CC       ECO:0000269|PubMed:18794797, ECO:0000269|PubMed:19573808,
CC       ECO:0000269|PubMed:23358419, ECO:0000269|PubMed:26158630,
CC       ECO:0000269|PubMed:27385333}.
CC   -!- PTM: Ubiquitinated by CHIP/STUB1. Ubiquitination is regulated by
CC       the HSP90 chaperone and regulates the receptor stability and
CC       activity through proteasomal degradation. ANKS1A prevents
CC       ubiquitination and degradation (By similarity). {ECO:0000250}.
CC   -!- DISEASE: Cataract 6, multiple types (CTRCT6) [MIM:116600]: An
CC       opacification of the crystalline lens of the eye that frequently
CC       results in visual impairment or blindness. Opacities vary in
CC       morphology, are often confined to a portion of the lens, and may
CC       be static or progressive. CTRCT6 includes posterior polar and age-
CC       related cortical cataracts, among others. Posterior polar cataract
CC       is a subcapsular opacity, usually disk-shaped, located at the back
CC       of the lens. Age-related cortical cataract is a developmental
CC       punctate opacity restricted to the cortex. The cataract is white
CC       or cerulean, increases in number with age, but rarely affects
CC       vision. {ECO:0000269|PubMed:19005574, ECO:0000269|PubMed:19306328,
CC       ECO:0000269|PubMed:19649315, ECO:0000269|PubMed:22570727}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Note=Overexpressed in several cancer types and promotes
CC       malignancy. {ECO:0000269|PubMed:19573808}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/EPHA2ID40462ch1p36.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M59371; AAA53375.1; -; mRNA.
DR   EMBL; EU826606; ACF47642.1; -; mRNA.
DR   EMBL; AL451042; CAH71943.1; -; Genomic_DNA.
DR   EMBL; CH471167; EAW51769.1; -; Genomic_DNA.
DR   EMBL; BC037166; AAH37166.1; -; mRNA.
DR   CCDS; CCDS169.1; -. [P29317-1]
DR   PIR; A36355; A36355.
DR   RefSeq; NP_004422.2; NM_004431.4. [P29317-1]
DR   UniGene; Hs.171596; -.
DR   PDB; 1MQB; X-ray; 2.30 A; A/B=596-900.
DR   PDB; 2E8N; NMR; -; A=902-976.
DR   PDB; 2K9Y; NMR; -; A/B=523-563.
DR   PDB; 2KSO; NMR; -; A=908-972.
DR   PDB; 2X10; X-ray; 3.00 A; A=27-534.
DR   PDB; 2X11; X-ray; 4.83 A; A=27-534.
DR   PDB; 3C8X; X-ray; 1.95 A; A=23-202.
DR   PDB; 3CZU; X-ray; 2.65 A; A=23-202.
DR   PDB; 3FL7; X-ray; 2.50 A; A=23-531.
DR   PDB; 3HEI; X-ray; 2.00 A; A/C/E/G/I/K/M/O=28-201.
DR   PDB; 3HPN; X-ray; 2.52 A; A/B/C/D/E/F=28-201.
DR   PDB; 3KKA; X-ray; 2.40 A; C/D/E=903-971.
DR   PDB; 3MBW; X-ray; 2.81 A; A=23-326.
DR   PDB; 3MX0; X-ray; 3.51 A; A/C=27-435.
DR   PDB; 3SKJ; X-ray; 2.50 A; E/F=23-202.
DR   PDB; 4P2K; X-ray; 1.50 A; A=590-876.
DR   PDB; 4PDO; X-ray; 2.10 A; A/B=590-876.
DR   PDB; 4TRL; X-ray; 2.45 A; A=590-876.
DR   PDB; 5EK7; X-ray; 1.90 A; A/B=583-876.
DR   PDB; 5I9U; X-ray; 1.89 A; A=596-900.
DR   PDB; 5I9V; X-ray; 1.46 A; A=596-900.
DR   PDB; 5I9W; X-ray; 1.36 A; A=596-900.
DR   PDB; 5I9X; X-ray; 1.43 A; A=596-900.
DR   PDB; 5I9Y; X-ray; 1.23 A; A=596-900.
DR   PDB; 5I9Z; X-ray; 1.70 A; A=596-900.
DR   PDB; 5IA0; X-ray; 1.95 A; A/B/C=596-900.
DR   PDB; 5IA1; X-ray; 2.04 A; A=596-900.
DR   PDB; 5IA2; X-ray; 1.62 A; A=596-900.
DR   PDB; 5IA3; X-ray; 1.79 A; A=596-900.
DR   PDB; 5IA4; X-ray; 1.80 A; A=596-900.
DR   PDB; 5IA5; X-ray; 1.78 A; A=596-900.
DR   PDBsum; 1MQB; -.
DR   PDBsum; 2E8N; -.
DR   PDBsum; 2K9Y; -.
DR   PDBsum; 2KSO; -.
DR   PDBsum; 2X10; -.
DR   PDBsum; 2X11; -.
DR   PDBsum; 3C8X; -.
DR   PDBsum; 3CZU; -.
DR   PDBsum; 3FL7; -.
DR   PDBsum; 3HEI; -.
DR   PDBsum; 3HPN; -.
DR   PDBsum; 3KKA; -.
DR   PDBsum; 3MBW; -.
DR   PDBsum; 3MX0; -.
DR   PDBsum; 3SKJ; -.
DR   PDBsum; 4P2K; -.
DR   PDBsum; 4PDO; -.
DR   PDBsum; 4TRL; -.
DR   PDBsum; 5EK7; -.
DR   PDBsum; 5I9U; -.
DR   PDBsum; 5I9V; -.
DR   PDBsum; 5I9W; -.
DR   PDBsum; 5I9X; -.
DR   PDBsum; 5I9Y; -.
DR   PDBsum; 5I9Z; -.
DR   PDBsum; 5IA0; -.
DR   PDBsum; 5IA1; -.
DR   PDBsum; 5IA2; -.
DR   PDBsum; 5IA3; -.
DR   PDBsum; 5IA4; -.
DR   PDBsum; 5IA5; -.
DR   ProteinModelPortal; P29317; -.
DR   SMR; P29317; -.
DR   BioGrid; 108288; 67.
DR   DIP; DIP-96N; -.
DR   IntAct; P29317; 30.
DR   MINT; MINT-3972729; -.
DR   STRING; 9606.ENSP00000351209; -.
DR   BindingDB; P29317; -.
DR   ChEMBL; CHEMBL2068; -.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester.
DR   DrugBank; DB08896; Regorafenib.
DR   GuidetoPHARMACOLOGY; 1822; -.
DR   iPTMnet; P29317; -.
DR   PhosphoSitePlus; P29317; -.
DR   SwissPalm; P29317; -.
DR   UniCarbKB; P29317; -.
DR   BioMuta; EPHA2; -.
DR   DMDM; 229462861; -.
DR   EPD; P29317; -.
DR   MaxQB; P29317; -.
DR   PaxDb; P29317; -.
DR   PeptideAtlas; P29317; -.
DR   PRIDE; P29317; -.
DR   DNASU; 1969; -.
DR   Ensembl; ENST00000358432; ENSP00000351209; ENSG00000142627. [P29317-1]
DR   GeneID; 1969; -.
DR   KEGG; hsa:1969; -.
DR   UCSC; uc001aya.2; human. [P29317-1]
DR   CTD; 1969; -.
DR   DisGeNET; 1969; -.
DR   GeneCards; EPHA2; -.
DR   HGNC; HGNC:3386; EPHA2.
DR   HPA; HPA066055; -.
DR   MalaCards; EPHA2; -.
DR   MIM; 116600; phenotype.
DR   MIM; 176946; gene.
DR   neXtProt; NX_P29317; -.
DR   OpenTargets; ENSG00000142627; -.
DR   Orphanet; 98993; Posterior polar cataract.
DR   Orphanet; 98994; Total congenital cataract.
DR   PharmGKB; PA27818; -.
DR   eggNOG; KOG0196; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118975; -.
DR   HOGENOM; HOG000233856; -.
DR   HOVERGEN; HBG062180; -.
DR   InParanoid; P29317; -.
DR   KO; K05103; -.
DR   OMA; CSPGFFK; -.
DR   OrthoDB; EOG091G00W0; -.
DR   PhylomeDB; P29317; -.
DR   TreeFam; TF315608; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   SignaLink; P29317; -.
DR   SIGNOR; P29317; -.
DR   EvolutionaryTrace; P29317; -.
DR   GeneWiki; EPH_receptor_A2; -.
DR   GenomeRNAi; 1969; -.
DR   PRO; PR:P29317; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000142627; -.
DR   CleanEx; HS_EPHA2; -.
DR   ExpressionAtlas; P29317; baseline and differential.
DR   Genevisible; P29317; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005622; C:intracellular; IEA:GOC.
DR   GO; GO:0030027; C:lamellipodium; IDA:UniProtKB.
DR   GO; GO:0031258; C:lamellipodium membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0031256; C:leading edge membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0032587; C:ruffle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0045296; F:cadherin binding; IDA:BHF-UCL.
DR   GO; GO:0005003; F:ephrin receptor activity; IEA:InterPro.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0090630; P:activation of GTPase activity; IMP:UniProtKB.
DR   GO; GO:0048320; P:axial mesoderm formation; IEA:Ensembl.
DR   GO; GO:0002043; P:blood vessel endothelial cell proliferation involved in sprouting angiogenesis; IEA:Ensembl.
DR   GO; GO:0046849; P:bone remodeling; ISS:UniProtKB.
DR   GO; GO:0060444; P:branching involved in mammary gland duct morphogenesis; ISS:UniProtKB.
DR   GO; GO:0046058; P:cAMP metabolic process; IMP:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0060326; P:cell chemotaxis; IMP:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0048870; P:cell motility; IMP:UniProtKB.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IEA:Ensembl.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IEA:Ensembl.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IDA:UniProtKB.
DR   GO; GO:0030216; P:keratinocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0070309; P:lens fiber cell morphogenesis; ISS:UniProtKB.
DR   GO; GO:0033598; P:mammary gland epithelial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0007275; P:multicellular organism development; TAS:ProtInc.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0032682; P:negative regulation of chemokine production; IEA:Ensembl.
DR   GO; GO:1901491; P:negative regulation of lymphangiogenesis; IEA:Ensembl.
DR   GO; GO:0051898; P:negative regulation of protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:0021915; P:neural tube development; IEA:Ensembl.
DR   GO; GO:0030182; P:neuron differentiation; IEA:Ensembl.
DR   GO; GO:0060035; P:notochord cell development; IEA:Ensembl.
DR   GO; GO:0014028; P:notochord formation; IEA:Ensembl.
DR   GO; GO:0001649; P:osteoblast differentiation; ISS:UniProtKB.
DR   GO; GO:0030316; P:osteoclast differentiation; ISS:UniProtKB.
DR   GO; GO:1904238; P:pericyte cell differentiation; IEA:Ensembl.
DR   GO; GO:0090004; P:positive regulation of establishment of protein localization to plasma membrane; IMP:UniProtKB.
DR   GO; GO:0036342; P:post-anal tail morphogenesis; IEA:Ensembl.
DR   GO; GO:0043491; P:protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:0045765; P:regulation of angiogenesis; ISS:UniProtKB.
DR   GO; GO:0043535; P:regulation of blood vessel endothelial cell migration; ISS:UniProtKB.
DR   GO; GO:0033628; P:regulation of cell adhesion mediated by integrin; IDA:UniProtKB.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0010591; P:regulation of lamellipodium assembly; IMP:UniProtKB.
DR   GO; GO:0070848; P:response to growth factor; IMP:UniProtKB.
DR   GO; GO:0001501; P:skeletal system development; IEA:Ensembl.
DR   GO; GO:0001570; P:vasculogenesis; IEA:Ensembl.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   CDD; cd10480; EphR_LBD_A2; 1.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 2.60.120.260; -; 1.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR027936; Eph_TM.
DR   InterPro; IPR034263; EphA2_rcpt_lig-bd.
DR   InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR008979; Galactose-bd-like.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016257; Tyr_kinase_ephrin_rcpt.
DR   InterPro; IPR001426; Tyr_kinase_rcpt_V_CS.
DR   Pfam; PF14575; EphA2_TM; 1.
DR   Pfam; PF01404; Ephrin_lbd; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00536; SAM_1; 1.
DR   PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00615; EPH_lbd; 1.
DR   SMART; SM01411; Ephrin_rec_like; 1.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00454; SAM; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 2.
DR   PROSITE; PS51550; EPH_LBD; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1.
DR   PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; Apoptosis;
KW   ATP-binding; Cataract; Cell adhesion; Cell junction; Cell membrane;
KW   Cell projection; Complete proteome; Differentiation; Disease mutation;
KW   Disulfide bond; Glycoprotein; Host-virus interaction; Kinase;
KW   Membrane; Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     23       {ECO:0000255}.
FT   CHAIN        24    976       Ephrin type-A receptor 2.
FT                                /FTId=PRO_0000016800.
FT   TOPO_DOM     24    537       Extracellular. {ECO:0000255}.
FT   TRANSMEM    538    558       Helical. {ECO:0000255}.
FT   TOPO_DOM    559    976       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       28    206       Eph LBD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00883}.
FT   DOMAIN      328    432       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      438    529       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      613    875       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      904    968       SAM. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00184}.
FT   NP_BIND     619    627       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION        1    206       Mediates interaction with CLDN4.
FT                                {ECO:0000269|PubMed:16236711}.
FT   REGION      606    906       Mediates interaction with ARHGEF16 and
FT                                ELMO2. {ECO:0000269|PubMed:20679435}.
FT   REGION      886    976       Negatively regulates interaction with
FT                                ARHGEF16. {ECO:0000269|PubMed:20679435}.
FT   MOTIF       974    976       PDZ-binding. {ECO:0000255}.
FT   COMPBIAS    188    325       Cys-rich.
FT   ACT_SITE    739    739       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     646    646       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     570    570       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     575    575       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     579    579       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     588    588       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     594    594       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q03145}.
FT   MOD_RES     628    628       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     647    647       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     735    735       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     772    772       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q03145}.
FT   MOD_RES     869    869       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     892    892       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     897    897       Phosphoserine; by PKB/AKT1, RPS6KA1,
FT                                RPS6KA3 AND PKA.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:19573808,
FT                                ECO:0000269|PubMed:26158630,
FT                                ECO:0000269|PubMed:27385333}.
FT   MOD_RES     901    901       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:27385333}.
FT   MOD_RES     921    921       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000255}.
FT   MOD_RES     930    930       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:23358419}.
FT   CARBOHYD    407    407       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    435    435       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   DISULFID     70    188
FT   DISULFID    105    115
FT   VAR_SEQ     477    497       GDSNSYNVRRTEGFSVTLDDL -> VTPRGAGLALAGPTAG
FT                                DRLVT (in isoform 2).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_056014.
FT   VAR_SEQ     498    976       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_056015.
FT   VARIANT      99     99       K -> N (in dbSNP:rs1058372).
FT                                /FTId=VAR_055989.
FT   VARIANT     391    391       G -> R (in dbSNP:rs34192549).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042121.
FT   VARIANT     511    511       T -> M (in dbSNP:rs55747232).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042122.
FT   VARIANT     568    568       R -> H (in dbSNP:rs56198600).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042123.
FT   VARIANT     631    631       M -> T (in dbSNP:rs34021505).
FT                                /FTId=VAR_055990.
FT   VARIANT     721    721       R -> Q (in CTRCT6; retained in the
FT                                cytoplasm and constitutively active it
FT                                alters EPHA2 signaling;
FT                                dbSNP:rs116506614).
FT                                {ECO:0000269|PubMed:19649315}.
FT                                /FTId=VAR_062532.
FT   VARIANT     777    777       G -> S (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042124.
FT   VARIANT     876    876       R -> H (in dbSNP:rs35903225).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042125.
FT   VARIANT     940    940       T -> I (in CTRCT6; reduced protein
FT                                stability and reduced ability to
FT                                stimulate cell migration in absence of
FT                                its ephrin ligand; dbSNP:rs137853200).
FT                                {ECO:0000269|PubMed:19306328,
FT                                ECO:0000269|PubMed:22570727}.
FT                                /FTId=VAR_058907.
FT   VARIANT     948    948       G -> W (in CTRCT6; reduced protein
FT                                stability and reduced ability to
FT                                stimulate cell migration in absence of
FT                                its ephrin ligand; dbSNP:rs137853199).
FT                                {ECO:0000269|PubMed:19005574,
FT                                ECO:0000269|PubMed:22570727}.
FT                                /FTId=VAR_058908.
FT   MUTAGEN     103    103       R->E: Significantly reduced response to
FT                                EFNA1. {ECO:0000269|PubMed:19525919}.
FT   MUTAGEN     646    646       K->M: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:16236711}.
FT   MUTAGEN     739    739       D->N: Increases serum-induced chemotaxis.
FT                                Loss of EFNA1-dependent regulation of
FT                                cell migration.
FT                                {ECO:0000269|PubMed:19573808}.
FT   MUTAGEN     897    897       S->A,D: Loss of serum-induced
FT                                phosphorylation by PKB. Loss of serum-
FT                                induced chemotaxis.
FT                                {ECO:0000269|PubMed:19573808}.
FT   CONFLICT     94     99       IFIELK -> NNFELN (in Ref. 1; AAA53375).
FT                                {ECO:0000305}.
FT   STRAND       28     33       {ECO:0000244|PDB:3C8X}.
FT   HELIX        34     36       {ECO:0000244|PDB:3C8X}.
FT   TURN         37     40       {ECO:0000244|PDB:3HPN}.
FT   STRAND       44     57       {ECO:0000244|PDB:3C8X}.
FT   STRAND       59     62       {ECO:0000244|PDB:3C8X}.
FT   STRAND       64     69       {ECO:0000244|PDB:3C8X}.
FT   STRAND       73     76       {ECO:0000244|PDB:3C8X}.
FT   STRAND       79     82       {ECO:0000244|PDB:3C8X}.
FT   STRAND       92    103       {ECO:0000244|PDB:3C8X}.
FT   HELIX       105    107       {ECO:0000244|PDB:3C8X}.
FT   STRAND      108    110       {ECO:0000244|PDB:3HEI}.
FT   TURN        112    114       {ECO:0000244|PDB:3SKJ}.
FT   STRAND      119    128       {ECO:0000244|PDB:3C8X}.
FT   HELIX       136    138       {ECO:0000244|PDB:3C8X}.
FT   STRAND      139    145       {ECO:0000244|PDB:3C8X}.
FT   STRAND      148    151       {ECO:0000244|PDB:3MBW}.
FT   HELIX       153    157       {ECO:0000244|PDB:3HEI}.
FT   STRAND      161    170       {ECO:0000244|PDB:3C8X}.
FT   STRAND      175    187       {ECO:0000244|PDB:3C8X}.
FT   STRAND      189    199       {ECO:0000244|PDB:3C8X}.
FT   STRAND      204    206       {ECO:0000244|PDB:3FL7}.
FT   STRAND      209    211       {ECO:0000244|PDB:3FL7}.
FT   STRAND      218    221       {ECO:0000244|PDB:3MBW}.
FT   STRAND      224    227       {ECO:0000244|PDB:3FL7}.
FT   STRAND      238    240       {ECO:0000244|PDB:3MBW}.
FT   STRAND      244    247       {ECO:0000244|PDB:3FL7}.
FT   STRAND      253    257       {ECO:0000244|PDB:3MBW}.
FT   STRAND      266    269       {ECO:0000244|PDB:3FL7}.
FT   STRAND      272    275       {ECO:0000244|PDB:3FL7}.
FT   STRAND      286    288       {ECO:0000244|PDB:3MBW}.
FT   STRAND      295    298       {ECO:0000244|PDB:3FL7}.
FT   STRAND      335    338       {ECO:0000244|PDB:3FL7}.
FT   STRAND      343    348       {ECO:0000244|PDB:3FL7}.
FT   STRAND      361    369       {ECO:0000244|PDB:3FL7}.
FT   STRAND      376    378       {ECO:0000244|PDB:3FL7}.
FT   STRAND      384    387       {ECO:0000244|PDB:3FL7}.
FT   STRAND      389    392       {ECO:0000244|PDB:3FL7}.
FT   STRAND      394    400       {ECO:0000244|PDB:3FL7}.
FT   STRAND      407    415       {ECO:0000244|PDB:3FL7}.
FT   HELIX       419    421       {ECO:0000244|PDB:3FL7}.
FT   STRAND      427    433       {ECO:0000244|PDB:3FL7}.
FT   STRAND      441    446       {ECO:0000244|PDB:3FL7}.
FT   STRAND      453    457       {ECO:0000244|PDB:3FL7}.
FT   TURN        460    465       {ECO:0000244|PDB:3FL7}.
FT   STRAND      467    475       {ECO:0000244|PDB:3FL7}.
FT   STRAND      483    493       {ECO:0000244|PDB:3FL7}.
FT   STRAND      502    510       {ECO:0000244|PDB:3FL7}.
FT   STRAND      522    525       {ECO:0000244|PDB:3FL7}.
FT   HELIX       536    556       {ECO:0000244|PDB:2K9Y}.
FT   STRAND      557    561       {ECO:0000244|PDB:2K9Y}.
FT   HELIX       591    594       {ECO:0000244|PDB:5EK7}.
FT   HELIX       597    600       {ECO:0000244|PDB:4PDO}.
FT   HELIX       601    604       {ECO:0000244|PDB:5I9Y}.
FT   HELIX       610    612       {ECO:0000244|PDB:5I9Y}.
FT   STRAND      613    621       {ECO:0000244|PDB:5I9Y}.
FT   STRAND      623    625       {ECO:0000244|PDB:5I9V}.
FT   STRAND      626    632       {ECO:0000244|PDB:5I9Y}.
FT   HELIX       635    637       {ECO:0000244|PDB:5I9V}.
FT   STRAND      641    648       {ECO:0000244|PDB:5I9Y}.
FT   HELIX       654    667       {ECO:0000244|PDB:5I9Y}.
FT   STRAND      678    682       {ECO:0000244|PDB:5I9Y}.
FT   STRAND      684    693       {ECO:0000244|PDB:5I9Y}.
FT   HELIX       700    706       {ECO:0000244|PDB:5I9Y}.
FT   TURN        707    709       {ECO:0000244|PDB:5I9Y}.
FT   HELIX       713    732       {ECO:0000244|PDB:5I9Y}.
FT   HELIX       742    744       {ECO:0000244|PDB:5I9Y}.
FT   STRAND      745    747       {ECO:0000244|PDB:5I9Y}.
FT   STRAND      753    755       {ECO:0000244|PDB:5I9Y}.
FT   HELIX       762    766       {ECO:0000244|PDB:5I9Y}.
FT   STRAND      776    779       {ECO:0000244|PDB:5EK7}.
FT   HELIX       781    783       {ECO:0000244|PDB:5I9Y}.
FT   HELIX       786    791       {ECO:0000244|PDB:5I9Y}.
FT   HELIX       796    811       {ECO:0000244|PDB:5I9Y}.
FT   TURN        817    820       {ECO:0000244|PDB:5I9Y}.
FT   HELIX       823    831       {ECO:0000244|PDB:5I9Y}.
FT   HELIX       844    853       {ECO:0000244|PDB:5I9Y}.
FT   HELIX       858    860       {ECO:0000244|PDB:5I9Y}.
FT   HELIX       864    876       {ECO:0000244|PDB:5I9Y}.
FT   HELIX       878    882       {ECO:0000244|PDB:5I9Y}.
FT   HELIX       884    887       {ECO:0000244|PDB:5IA0}.
FT   HELIX       909    915       {ECO:0000244|PDB:3KKA}.
FT   HELIX       919    921       {ECO:0000244|PDB:3KKA}.
FT   HELIX       922    927       {ECO:0000244|PDB:3KKA}.
FT   HELIX       933    937       {ECO:0000244|PDB:3KKA}.
FT   HELIX       941    946       {ECO:0000244|PDB:3KKA}.
FT   HELIX       952    964       {ECO:0000244|PDB:3KKA}.
SQ   SEQUENCE   976 AA;  108266 MW;  845D7E1BBCCAACCC CRC64;
     MELQAARACF ALLWGCALAA AAAAQGKEVV LLDFAAAGGE LGWLTHPYGK GWDLMQNIMN
     DMPIYMYSVC NVMSGDQDNW LRTNWVYRGE AERIFIELKF TVRDCNSFPG GASSCKETFN
     LYYAESDLDY GTNFQKRLFT KIDTIAPDEI TVSSDFEARH VKLNVEERSV GPLTRKGFYL
     AFQDIGACVA LLSVRVYYKK CPELLQGLAH FPETIAGSDA PSLATVAGTC VDHAVVPPGG
     EEPRMHCAVD GEWLVPIGQC LCQAGYEKVE DACQACSPGF FKFEASESPC LECPEHTLPS
     PEGATSCECE EGFFRAPQDP ASMPCTRPPS APHYLTAVGM GAKVELRWTP PQDSGGREDI
     VYSVTCEQCW PESGECGPCE ASVRYSEPPH GLTRTSVTVS DLEPHMNYTF TVEARNGVSG
     LVTSRSFRTA SVSINQTEPP KVRLEGRSTT SLSVSWSIPP PQQSRVWKYE VTYRKKGDSN
     SYNVRRTEGF SVTLDDLAPD TTYLVQVQAL TQEGQGAGSK VHEFQTLSPE GSGNLAVIGG
     VAVGVVLLLV LAGVGFFIHR RRKNQRARQS PEDVYFSKSE QLKPLKTYVD PHTYEDPNQA
     VLKFTTEIHP SCVTRQKVIG AGEFGEVYKG MLKTSSGKKE VPVAIKTLKA GYTEKQRVDF
     LGEAGIMGQF SHHNIIRLEG VISKYKPMMI ITEYMENGAL DKFLREKDGE FSVLQLVGML
     RGIAAGMKYL ANMNYVHRDL AARNILVNSN LVCKVSDFGL SRVLEDDPEA TYTTSGGKIP
     IRWTAPEAIS YRKFTSASDV WSFGIVMWEV MTYGERPYWE LSNHEVMKAI NDGFRLPTPM
     DCPSAIYQLM MQCWQQERAR RPKFADIVSI LDKLIRAPDS LKTLADFDPR VSIRLPSTSG
     SEGVPFRTVS EWLESIKMQQ YTEHFMAAGY TAIEKVVQMT NDDIKRIGVR LPGHQKRIAY
     SLLGLKDQVN TVGIPI
//
